PL BioScience Announces Major Site Expansion

PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, announced a significant expansion of its company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements.

The facility will serve as a hub for research and product innovation, supporting the development of next-generation HPL-based media, such as artificial HPL.

Located in Aachen, Germany, the new headquarters offers over 1,200 square meters, with dedicated production and storage areas alongside office space to accommodate the company’s continued growth. The expansion will enable the company to produce up to 20,000L of GMP-grade HPL per year. It will also provide more highly skilled jobs in the region.

HPL is produced from artificial platelets via a proprietary process, which can be developed into a nearly unlimited supply of a superior cell culture supplement. Other advanced products are in development, including specialized products tailored to the needs of different cell manufacturing applications, such as CAR-T cell manufacturing.

This large in-house production capacity makes PL BioScience the first company in the HPL industry with a two-source, GMP-grade strategy when combined with the current production hub.

The opening of the new headquarters is a key milestone in PL BioScience’s long-term strategy to deliver high-quality cell culture supplements to customers and meet increasing global demand for its products. The company will move to the new facility, integrating operations under a shared organizational vision, in September 2025.

“This is a major step forward for PL BioScience,” said Dr. Hatim Hemeda, CEO of the German biotech. “With the new headquarters, we are accelerating our growth and strengthening our future production capabilities in response to growing global demand for HPL products. In addition, this expansion marks a significant step toward accelerating product innovation, including the further development of our new artificial HPL, the world’s first scalable, fully lab- made HPL solution.”